MA44935A1 - Compositions pharmaceutiques contenant un antagoniste de l'intégrine alpha 4 , utilisée pour le traitement d"affections inflammatoires oculaires - Google Patents

Compositions pharmaceutiques contenant un antagoniste de l'intégrine alpha 4 , utilisée pour le traitement d"affections inflammatoires oculaires

Info

Publication number
MA44935A1
MA44935A1 MA44935A MA44935A MA44935A1 MA 44935 A1 MA44935 A1 MA 44935A1 MA 44935 A MA44935 A MA 44935A MA 44935 A MA44935 A MA 44935A MA 44935 A1 MA44935 A1 MA 44935A1
Authority
MA
Morocco
Prior art keywords
pharmaceutical compositions
eye
alpha
treatment
inflammatory conditions
Prior art date
Application number
MA44935A
Other languages
English (en)
Inventor
Achim Hans-Peter Krauss
Original Assignee
Axerovision Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axerovision Inc filed Critical Axerovision Inc
Publication of MA44935A1 publication Critical patent/MA44935A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne des antagonistes de l'intégrine alpha 4 et leur utilisation dans des compositions pharmaceutiques, principalement des compositions ophtalmiques administrées par voie topique. Ces compositions pharmaceutiques sont utiles pour le traitement des affections inflammatoires oculaires, par exemple la sécheresse oculaire, les uvéites non-infectieuses (par exemple, l'uvéite antérieure, postérieure, intermédiaire, la panuvéite), l'iritis, la sclérite ou la conjonctivite non-infectieux chez les animaux, et en particulier chez les mammifères, y compris chez les êtres humains.
MA44935A 2015-07-08 2018-02-08 Compositions pharmaceutiques contenant un antagoniste de l'intégrine alpha 4 , utilisée pour le traitement d"affections inflammatoires oculaires MA44935A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562189813P 2015-07-08 2015-07-08

Publications (1)

Publication Number Publication Date
MA44935A1 true MA44935A1 (fr) 2019-08-30

Family

ID=56373100

Family Applications (2)

Application Number Title Priority Date Filing Date
MA42016A MA42016A1 (fr) 2015-07-08 2016-07-07 Compositions pharmaceutiques contenant un antagoniste de l'intégrine alpha 4, utilisées pour le traitement d''affections inflammatoires oculaires
MA44935A MA44935A1 (fr) 2015-07-08 2018-02-08 Compositions pharmaceutiques contenant un antagoniste de l'intégrine alpha 4 , utilisée pour le traitement d"affections inflammatoires oculaires

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA42016A MA42016A1 (fr) 2015-07-08 2016-07-07 Compositions pharmaceutiques contenant un antagoniste de l'intégrine alpha 4, utilisées pour le traitement d''affections inflammatoires oculaires

Country Status (21)

Country Link
US (3) US10413535B2 (fr)
EP (1) EP3319639B1 (fr)
JP (2) JP6752276B2 (fr)
KR (2) KR20220062688A (fr)
CN (1) CN107921136A (fr)
AU (1) AU2016290197B2 (fr)
BR (1) BR112018000112A2 (fr)
CA (1) CA2989522C (fr)
CL (1) CL2018000057A1 (fr)
ES (1) ES2835274T3 (fr)
HK (1) HK1247120A1 (fr)
IL (2) IL256770B (fr)
MA (2) MA42016A1 (fr)
MX (1) MX385229B (fr)
MY (1) MY187552A (fr)
PL (1) PL3319639T3 (fr)
RU (1) RU2018103940A (fr)
TN (1) TN2017000538A1 (fr)
UA (1) UA123728C2 (fr)
WO (1) WO2017006272A1 (fr)
ZA (1) ZA201708601B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200004789A (ko) * 2017-03-09 2020-01-14 알리스타 파마슈티컬즈, 인크. 안구 건조증 질환을 위한 펩티드
US10555947B2 (en) * 2017-05-19 2020-02-11 Ocugen, Inc. Ophthalmic compositions and methods of use
KR102630416B1 (ko) 2018-10-30 2024-02-01 길리애드 사이언시즈, 인코포레이티드 알파4베타7 인테그린 억제제로서의 퀴놀린 유도체
AU2019373242B2 (en) 2018-10-30 2023-07-13 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
ES3013256T3 (en) 2018-10-30 2025-04-11 Gilead Sciences Inc Imidazo[1,2-a]pyridine derivatives as alpha4beta7 integrin inhibitors for the treatment of inflammatory diseases
US11179383B2 (en) 2018-10-30 2021-11-23 Gilead Sciences, Inc. Compounds for inhibition of α4β7 integrin
EP4003392A4 (fr) * 2019-07-26 2023-08-09 Allegro Pharmaceuticals, LLC Peptides pour le traitement de la dégénérescence maculaire non-exsudative et d'autres troubles de l'oeil
CN114222730B (zh) 2019-08-14 2024-09-10 吉利德科学公司 用于抑制α4β7整合素的化合物
US20240158375A1 (en) * 2020-10-21 2024-05-16 Azura Ophthalmics Ltd. Compounds and methods for the treatment of ocular disorders
KR102391198B1 (ko) * 2021-08-27 2022-04-27 한림제약(주) 리피테그라스트 또는 이의 약제학적으로 허용가능한 염을 포함하는 수용액 형태의 점안액 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9828074D0 (en) * 1998-12-18 1999-02-17 Glaxo Group Ltd Therapeutically useful compounds
GB0014892D0 (en) * 2000-06-16 2000-08-09 Glaxo Group Ltd Novel pharmaceutical formulation
US8168655B2 (en) * 2005-05-17 2012-05-01 Sarcode Bioscience Inc. Compositions and methods for treatment of eye disorders
ZA200804550B (en) * 2005-11-09 2009-08-26 Combinatorx Inc Methods, compositions, and kits for the treatment of medical conditions
US20130217657A1 (en) * 2011-12-21 2013-08-22 Insite Vision Incorporated Combination anti-inflammatory ophthalmic compositions

Also Published As

Publication number Publication date
US20200000786A1 (en) 2020-01-02
US10413535B2 (en) 2019-09-17
MA42016A1 (fr) 2018-03-30
UA123728C2 (uk) 2021-05-26
KR102440162B1 (ko) 2022-09-02
TN2017000538A1 (en) 2019-04-12
MX385229B (es) 2025-03-14
US10751334B2 (en) 2020-08-25
IL256770B (en) 2021-02-28
KR20220062688A (ko) 2022-05-17
JP2018521126A (ja) 2018-08-02
CA2989522C (fr) 2022-10-18
CL2018000057A1 (es) 2018-06-22
US20180200240A1 (en) 2018-07-19
PL3319639T3 (pl) 2021-03-08
WO2017006272A1 (fr) 2017-01-12
CN107921136A (zh) 2018-04-17
HK1247120A1 (zh) 2018-09-21
KR20180041122A (ko) 2018-04-23
ZA201708601B (en) 2019-05-29
AU2016290197B2 (en) 2021-07-22
JP2020121985A (ja) 2020-08-13
CA2989522A1 (fr) 2017-01-12
IL280827A (en) 2021-04-29
MX2017017163A (es) 2018-08-09
IL256770A (en) 2018-03-29
EP3319639B1 (fr) 2020-11-18
RU2018103940A (ru) 2019-08-08
JP6752276B2 (ja) 2020-09-09
US20200405703A1 (en) 2020-12-31
AU2016290197A1 (en) 2018-01-04
ES2835274T3 (es) 2021-06-22
EP3319639A1 (fr) 2018-05-16
MY187552A (en) 2021-09-29
BR112018000112A2 (pt) 2018-09-04
RU2018103940A3 (fr) 2019-09-03

Similar Documents

Publication Publication Date Title
MA42016A1 (fr) Compositions pharmaceutiques contenant un antagoniste de l'intégrine alpha 4, utilisées pour le traitement d''affections inflammatoires oculaires
MX381639B (es) Composicion oftalmica para el tratamiento de la enfermedad del ojo seco.
MX381313B (es) Derivados de benzimidazol como moduladores de ror-gamma
MA56226B1 (fr) Antagoniste du récepteur crf1, formulations pharmaceutiques et ses formes solides pour le traitement de l'hyperplasie surrénale congénitale
MX388457B (es) Inhibidores de imidazopirazina de la tirosina cinasa de bruton.
FR25C1042I1 (fr) Composition pharmaceutique pour la prévention et/ou le traitement de la dermatite atopique contenant comme principe actif un antagoniste de l'il-31
EA201691242A1 (ru) Фармацевтические композиции, содержащие azd9291
EA201691516A1 (ru) Дигидропирролопиридиновые ингибиторы ror-гамма
MA44674B1 (fr) Inhibiteurs de bromodomaine
MX375752B (es) Inhibidores de tirosina quinasa de bruton.
EP3829569A4 (fr) Formulations de spinosyne pour le traitement de maladies oculaires et faciaux provoquées par demodex
EP3672587A4 (fr) Compositions pharmaceutiques destinées au traitement d'affections ophtalmiques
EA201591541A1 (ru) Ингибиторы бета-секретазы 1 (bace 1)
MA38253A1 (fr) Compositions comprenant de la vortioxétine et du donépézil
EA201590066A1 (ru) Дифторгексагидроциклопентаоксазинилы и дифторгексагидробензоксазинилы в качестве ингибиторов бета-секретазы 1
EP3804736A4 (fr) Composition pharmaceutique comprenant des cellules souches mésenchymateuses en tant qu'ingrédient efficace pour la prévention ou le traitement d'une maladie inflammatoire
MA39447B1 (fr) Pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
EP3570835A4 (fr) Méthodes et compositions pharmaceutiques pour la prévention ou le traitement d'affections dermiques immuno-inflammatoires
MA41985B1 (fr) Composition pour le nettoyage du côlon et le traitement de troubles gastro-intestinaux
EP3650029A4 (fr) Composition pharmaceutique pour la prévention et le traitement de la néphropathie diabétique, contenant un dérivé d'adénosine
EP3946433A4 (fr) Compositions, dispositifs et méthodes de traitement de la maladie de fabry
EA201990550A1 (ru) Офтальмологический препарат, включающий азоловое соединение
MA44660B1 (fr) (+) -azasetron pour son utilisation dans le traitement des troubles de l'oreille
MA39448A1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
EP3603647A4 (fr) Composition pharmaceutique pour la prévention et le traitement du glaucome, contenant un dérivé d'adénosine